Industry
Biotechnology
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 15, 2024 | 12:20 pm
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 1:22 pm
Portfolio Pulse from Benzinga Newsdesk
July 01, 2024 | 3:29 pm
Portfolio Pulse from Benzinga Newsdesk
June 17, 2024 | 1:29 pm
Portfolio Pulse from Benzinga Newsdesk
June 14, 2024 | 10:09 am
Portfolio Pulse from Benzinga Newsdesk
June 12, 2024 | 11:43 am
Portfolio Pulse from Benzinga Newsdesk
June 03, 2024 | 10:06 am
Portfolio Pulse from Benzinga Newsdesk
May 10, 2024 | 4:48 pm
Portfolio Pulse from Benzinga Newsdesk
May 09, 2024 | 10:16 am
Portfolio Pulse from Benzinga Newsdesk
May 03, 2024 | 9:36 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.